CCM
NVS icon

Carlson Capital Management’s Novartis NVS Stock Holding History

Carlson Capital Management’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,315
Closed -$335K – 172
2023
Q4 		$335K Buy
+3,315
New +$320K 0.02% 147

Other funds holding NVS

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Carlson Capital Management's NVS Position: Q1 2024 in Review

Carlson Capital Management sold out of Novartis (NVS) in Q1 2024, closing a stake of 3,315 shares — an estimated $335K sold.

Carlson Capital Management first reported a position in NVS in Q4 2023 and held it in 1 quarter. The position peaked at $335K in Q4 2023. 1,253 funds tracked by Wall St. Rank hold NVS as of Q1 2024.

  • Carlson Capital Management reported no remaining Novartis position as of Q1 2024 after selling out during the quarter.
  • Carlson Capital Management sold 3,315 Novartis shares in Q1 2024, an estimated $335K.
  • Carlson Capital Management first reported a position in Novartis in Q4 2023 and held it in 1 quarter.
  • Carlson Capital Management's Novartis position peaked at $335K in Q4 2023.
  • 1,253 funds tracked by Wall St. Rank held Novartis as of Q1 2024.

Based on Carlson Capital Management's 13F filing for Q1 2024, filed 12 Apr 2024.